Rani Therapeutics announces promising phase 1 results for oral Stelara biosimilar 06-Feb-2024 By Isabel Cameron Rani Therapeutics, a clinical-stage biotherapeutics company focused on the oral delivery of biologics, has announced encouraging results from its phase 1 study of RT-111, a RaniPill capsule containing an ustekinumab biosimilar, CT-P43.